Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

Recruiting in Palo Alto (17 mi)

+1 other location

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: AbbVie

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study will assess how safe ABBV-154 is and how ABBV-154 moves through the body of adult healthy participants. Adverse Events will be assessed. ABBV-154 is an investigational drug being developed for potential treatment of immune-mediated inflammatory diseases. Participants are randomly assigned to one of the 2 treatment groups. Approximately 40 adult healthy volunteers will be enrolled in 2 sites in the United States. All participants will receive ABBV-154 as subcutaneous injections with one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 9 days. Adverse Events and blood tests will be performed.

Eligibility Criteria

Inclusion Criteria

- Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounding to the nearest tenth at screening and upon initial confinement.

Participant Groups

Group I: ABBV-154 Dose B Experimental Treatment 1 Intervention

Participants will receive subcutaneous dose of ABBV-154 Dose Formulation B.

Group II: ABBV-154 Dose A Experimental Treatment 1 Intervention

Participants will receive subcutaneous dose of ABBV-154 Dose Formulation A.

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

PPD Clinical Research Unit -Las Vegas /ID# 250650 Las Vegas, NV

Acpru /Id# 250429 Grayslake, IL

Who Is Running the Clinical Trial?

AbbVie Lead Sponsor

References